Baillie Gifford & Co Portfolio holdings
Baillie Gifford & Co., founded in 1908 by Lt Col Augustus Baillie and Carlyle Gifford and headquartered in Edinburgh, Scotland, is an independent, partnership-owned investment management firm renowned for its long-term, growth-oriented approach, managing over £230 billion ($290 billion USD) in assets as of late 2024. Focusing primarily on global equities, the firm serves institutional clients like pension funds and retail investors through mutual funds and investment trusts, such as the Scottish Mortgage Investment Trust, emphasizing fundamental research into innovative, high-growth companies—often holding stakes in firms like Tesla and Amazon for decades. With around 2,000 employees across offices in London, New York, Hong Kong, and beyond, Baillie Gifford operates without external ownership pressures, allowing its 58 partners to prioritize patience and conviction over short-term market trends. Known for its low-profile culture and ESG integration, the firm has earned a reputation as a thoughtful, contrarian investor in a world of rapid-fire trading.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Trip.com Group
TCOM
|
+$550M |
| 2 |
DexCom
DXCM
|
+$499M |
| 3 |
ResMed
RMD
|
+$343M |
| 4 |
MBLY
Mobileye N.V.
MBLY
|
+$306M |
| 5 |
NVIDIA
NVDA
|
+$298M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
WFM
Whole Foods Market Inc
WFM
|
+$305M |
| 2 |
American Express
AXP
|
+$256M |
| 3 |
LNKD
LinkedIn Corporation
LNKD
|
+$162M |
| 4 |
Stellantis
STLA
|
+$117M |
| 5 |
Ryanair
RYAAY
|
+$66.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 35.19% |
| 2 | Communication Services | 18.4% |
| 3 | Healthcare | 14.19% |
| 4 | Financials | 8.31% |
| 5 | Technology | 8.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
176
EPAM Systems
EPAM
$5.54B
| $5.88M | 0.01% |
84,900
| – | – |
|
177
Codexis
CDXS
$157M
| $5.26M | 0.01% |
1,185,133
| – | – |
|
178
Microchip Technology
MCHP
$42.8B
| $5.14M | 0.01% |
165,320
| – | – |
|
|
LXFT
179
DELISTED
Luxoft Holding, Inc.
LXFT
| $5.12M | 0.01% |
96,930
+68,500
| +241% | +$3.65M |
|
180
Power Integrations
POWI
$3.5B
| $5.08M | 0.01% |
161,360
| – | – |
|
|
FMI
181
DELISTED
Foundation Medicine, Inc.
FMI
| $4.08M | 0.01% |
174,800
| – | – |
|
182
Regeneron Pharmaceuticals
REGN
$77.9B
| $4.06M | 0.01% |
10,100
| – | – |
|
183
SK Telecom
SKM
$13.5B
| $4.04M | 0.01% |
108,595
-4,959
| -4% | -$180K |
|
|
KDNY
184
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $3.6M | 0.01% |
58,000
| – | – |
|
185
Protalix BioTherapeutics
PLX
$190M
| $3.56M | 0.01% |
636,136
| – | – |
|
186
Wipro
WIT
$20B
| $3.36M | 0.01% |
1,843,344
+528,213
| +40% | +$1.08M |
|
187
Weibo
WB
$1.99B
| $3.07M | ﹤0.01% |
+61,182
| New | +$2.53M |
|
|
BIOA
188
DELISTED
BioAmber Inc.
BIOA
| $2.46M | ﹤0.01% |
579,540
| – | – |
|
189
Acacia Research
ACTG
$446M
| $2.39M | ﹤0.01% |
365,820
| – | – |
|
190
Rio Tinto
RIO
$161B
| $2.36M | ﹤0.01% |
70,626
| – | – |
|
|
ONC
191
BeOne Medicines Ltd
ONC
$32.9B
| $2.12M | ﹤0.01% |
68,835
+635
| +0.9% | +$18.4K |
|
|
FOMX
192
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
| $2.03M | ﹤0.01% |
219,400
| – | – |
|
193
HUTCHMED
HCM
$2.02B
| $1.83M | ﹤0.01% |
152,926
+3,116
| +2% | +$39.8K |
|
194
NetEase
NTES
$83.4B
| $302K | ﹤0.01% |
+6,265
| New | +$267K |
|
195
Korea Electric Power
KEP
$15.8B
| $46K | ﹤0.01% |
+1,900
| New | +$50.1K |
|
196
Danaher
DHR
$136B
| – | – |
-287,007
| Closed | -$19.5M |
|
197
PayPal
PYPL
$49.5B
| – | – |
-151,960
| Closed | -$5.55M |
|
198
Qualcomm
QCOM
$167B
| – | – |
-414,756
| Closed | -$22.2M |
|
|
SNMX
199
DELISTED
Senomyx, Inc.
SNMX
| – | – |
-121,665
| Closed | -$334K |
|
|
VALE.P
200
DELISTED
Vale S A
VALE.P
| – | – |
-323,000
| Closed | -$1.29M |
|
Similar funds
Baillie Gifford & Co's Q3 2016 Portfolio in Review
As of Q3 2016, Baillie Gifford & Co held 202 positions worth $63.9B, up 14% from $56.1B the previous quarter. Its ten largest holdings account for 50% of the portfolio.
Baillie Gifford & Co's Q3 2016 filing shows 9 new, 37 increased, 100 reduced and 7 closed positions. Its largest new stake was ResMed: 5,150,770 shares worth $334M. The largest sale was Whole Foods Market Inc, an estimated $305M.
By sector, the portfolio is most concentrated in Consumer Discretionary at 35% of assets, up from 34% a quarter earlier, followed by Communication Services and Healthcare.
- Baillie Gifford & Co's largest Q3 2016 buy was ResMed: 5,150,770 shares worth $334M.
- Baillie Gifford & Co added most to Trip.com Group in Q3 2016, an estimated $550M increase.
- Baillie Gifford & Co's biggest Q3 2016 reduction was Whole Foods Market Inc, cutting an estimated $305M.
- Baillie Gifford & Co fully exited LinkedIn Corporation in Q3 2016, selling an estimated $162M.
- Baillie Gifford & Co's ten largest holdings make up 50% of its $63.9B portfolio in Q3 2016.
- Baillie Gifford & Co opened 9 new positions and closed 7 in Q3 2016.
- Baillie Gifford & Co's portfolio value rose 14% quarter-over-quarter to $63.9B.
Based on Baillie Gifford & Co's 13F filing for Q3 2016, filed 9 Nov 2016.